Emerging evidence implicates tau in the pathology of HD, akin to tauopathies, suggesting that therapeutic strategies targeting tau dysfunction, ranging from small molecules to gene modulation approaches, could hold promise for addressing cognitive decline in HD [185]. Here, MAPT is linked to Huntington disease.